Skip Nav Destination
Issues
1 December 2016
-
Cover Image
Cover Image
The cover shows a section of serous endometrial carcinoma with irregular glandular spaces, marked nuclear atypia and focal necrosis. The peritumoral lymphocytes demonstrated diffuse, weak-to-moderate PD-L1 immunoreactivity. For details, see the article by Santin and colleagues on page 5682 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Statistics in CCR
Molecular Pathways
Reviews
Cancer Therapy: Clinical
Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial
Teresa Caballero-Velázquez; on behalf of the GETH (Grupo Español de Trasplante Hematopoyético); Isabel Montero; on behalf of the GETH (Grupo Español de Trasplante Hematopoyético); Fermín Sánchez-Guijo; on behalf of the GETH (Grupo Español de Trasplante Hematopoyético); Rocío Parody; on behalf of the GETH (Grupo Español de Trasplante Hematopoyético); Raquel Saldaña; on behalf of the GETH (Grupo Español de Trasplante Hematopoyético); David Valcarcel; on behalf of the GETH (Grupo Español de Trasplante Hematopoyético); Oriana López-Godino; on behalf of the GETH (Grupo Español de Trasplante Hematopoyético); Christelle Ferra i Coll; on behalf of the GETH (Grupo Español de Trasplante Hematopoyético); Marian Cuesta; on behalf of the GETH (Grupo Español de Trasplante Hematopoyético); Antonio Carrillo-Vico; on behalf of the GETH (Grupo Español de Trasplante Hematopoyético); Luis I. Sánchez-Abarca; on behalf of the GETH (Grupo Español de Trasplante Hematopoyético); Lucía López-Corral; on behalf of the GETH (Grupo Español de Trasplante Hematopoyético); Francisco J. Márquez-Malaver; on behalf of the GETH (Grupo Español de Trasplante Hematopoyético); José A. Pérez-Simón; on behalf of the GETH (Grupo Español de Trasplante Hematopoyético)
Author Choice
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma
Noopur S. Raje; Edward A. Faber, Jr; Paul G. Richardson; Gary Schiller; Raymond J. Hohl; Adam D. Cohen; Andres Forero; Susan Carpenter; Tuan S. Nguyen; Ilaria Conti; Christopher J. Kaiser; Damien M. Cronier; James E. Wooldridge; Kenneth C. Anderson
Author Choice
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
Jeffrey R. Infante; Philippe A. Cassier; John F. Gerecitano; Petronella O. Witteveen; Rashmi Chugh; Vincent Ribrag; Abhijit Chakraborty; Alessandro Matano; Jason R. Dobson; Adam S. Crystal; Sudha Parasuraman; Geoffrey I. Shapiro
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis
Zahi Mitri; on behalf of the Translational Breast Cancer Research Consortium; Rita Nanda; on behalf of the Translational Breast Cancer Research Consortium; Kimberly Blackwell; on behalf of the Translational Breast Cancer Research Consortium; Colleen M. Costelloe; on behalf of the Translational Breast Cancer Research Consortium; Ilona Hood; on behalf of the Translational Breast Cancer Research Consortium; Caimiao Wei; on behalf of the Translational Breast Cancer Research Consortium; Abenaa M. Brewster; on behalf of the Translational Breast Cancer Research Consortium; Nuhad K. Ibrahim; on behalf of the Translational Breast Cancer Research Consortium; Kimberly B. Koenig; on behalf of the Translational Breast Cancer Research Consortium; Gabriel N. Hortobagyi; on behalf of the Translational Breast Cancer Research Consortium; Catherine Van Poznak; on behalf of the Translational Breast Cancer Research Consortium; Mothaffar F. Rimawi; on behalf of the Translational Breast Cancer Research Consortium; Stacy Moulder-Thompson; on behalf of the Translational Breast Cancer Research Consortium
Author Choice
Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents
Allan Lipton; Matthew R. Smith; Karim Fizazi; Alison T. Stopeck; David Henry; Janet E. Brown; Neal D. Shore; Fred Saad; Andrew Spencer; Li Zhu; Douglas J. Warner
Author Choice
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling
Heather L. McArthur; Adi Diab; David B. Page; Jianda Yuan; Stephen B. Solomon; Virgilio Sacchini; Christopher Comstock; Jeremy C. Durack; Majid Maybody; Janice Sung; Arielle Ginsberg; Phillip Wong; Afsar Barlas; Zhiwan Dong; Chunjun Zhao; Brian Blum; Sujata Patil; Deirdre Neville; Elizabeth A. Comen; Elizabeth A. Morris; Alan Kotin; Edi Brogi; Y. Hannah Wen; Monica Morrow; Mario E. Lacouture; Padmanee Sharma; James P. Allison; Clifford A. Hudis; Jedd D. Wolchok; Larry Norton
Personalized Medicine and Imaging
Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients
Remy B. Verheijen; on behalf of the Dutch Pharmacology Oncology Group; Sander Bins; on behalf of the Dutch Pharmacology Oncology Group; Ron H.J. Mathijssen; on behalf of the Dutch Pharmacology Oncology Group; Martijn P. Lolkema; on behalf of the Dutch Pharmacology Oncology Group; Leni van Doorn; on behalf of the Dutch Pharmacology Oncology Group; Jan H.M. Schellens; on behalf of the Dutch Pharmacology Oncology Group; Jos H. Beijnen; on behalf of the Dutch Pharmacology Oncology Group; Marlies H.G. Langenberg; on behalf of the Dutch Pharmacology Oncology Group; Alwin D.R. Huitema; on behalf of the Dutch Pharmacology Oncology Group; Neeltje Steeghs; on behalf of the Dutch Pharmacology Oncology Group
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
Barbara Ingold Heppner; Michael Untch; Carsten Denkert; Berit M. Pfitzner; Bianca Lederer; Wolfgang Schmitt; Holger Eidtmann; Peter A. Fasching; Hans Tesch; Christine Solbach; Mahdi Rezai; Dirk M. Zahm; Frank Holms; Manfred Glados; Petra Krabisch; Esther Heck; Angelika Ober; Petra Lorenz; Kurt Diebold; Jörg-Olaf Habeck; Sibylle Loibl
Author Choice
TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer
Rinath Jeselsohn; William T. Barry; Ilenia Migliaccio; Chiara Biagioni; Jin Zhao; Jonas De Tribolet-Hardy; Cristina Guarducci; Martina Bonechi; Naomi Laing; Eric P. Winer; Myles Brown; Angelo Di Leo; Luca Malorni
Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response
Philipp Kickingereder; Michael Götz; John Muschelli; Antje Wick; Ulf Neuberger; Russell T. Shinohara; Martin Sill; Martha Nowosielski; Heinz-Peter Schlemmer; Alexander Radbruch; Wolfgang Wick; Martin Bendszus; Klaus H. Maier-Hein; David Bonekamp
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Jeffrey C. Thompson; Stephanie S. Yee; Andrea B. Troxel; Samantha L. Savitch; Ryan Fan; David Balli; David B. Lieberman; Jennifer D. Morrissette; Tracey L. Evans; Joshua Bauml; Charu Aggarwal; John A. Kosteva; Evan Alley; Christine Ciunci; Roger B. Cohen; Stephen Bagley; Susan Stonehouse-Lee; Victoria E. Sherry; Elizabeth Gilbert; Corey Langer; Anil Vachani; Erica L. Carpenter
Author Choice
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma
Charlotte Pawlyn; Martin F. Kaiser; Christoph Heuck; Lorenzo Melchor; Christopher P. Wardell; Alex Murison; Shweta S. Chavan; David C. Johnson; Dil B. Begum; Nasrin M. Dahir; Paula Z. Proszek; David A. Cairns; Eileen M. Boyle; John R. Jones; Gordon Cook; Mark T. Drayson; Roger G. Owen; Walter M. Gregory; Graham H. Jackson; Bart Barlogie; Faith E. Davies; Brian A. Walker; Gareth J. Morgan
Cancer Therapy: Preclinical
Author Choice
Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion/Differentiation and Preclinical Proof of Concept
Afonso R. Almeida; Daniel V. Correia; Ana Fernandes-Platzgummer; Cláudia L. da Silva; Maria Gomes da Silva; Diogo Remechido Anjos; Bruno Silva-Santos
PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo
Heike Niessner; Jennifer Schmitz; Ghazaleh Tabatabai; Andreas M. Schmid; Carsten Calaminus; Tobias Sinnberg; Benjamin Weide; Thomas K. Eigentler; Claus Garbe; Birgit Schittek; Leticia Quintanilla-Fend; Benjamin Bender; Marion Mai; Christian Praetorius; Stefan Beissert; Gabriele Schackert; Michael H. Muders; Matthias Meinhardt; Gustavo B. Baretton; Reinhard Dummer; Keith Flaherty; Bernd J. Pichler; Dagmar Kulms; Dana Westphal; Friedegund Meier
Author Choice
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
Uwe Reusch; Kimberly H. Harrington; Chelsea J. Gudgeon; Ivica Fucek; Kristina Ellwanger; Michael Weichel; Stefan H.J. Knackmuss; Eugene A. Zhukovsky; Judith A. Fox; Lori A. Kunkel; Jeanmarie Guenot; Roland B. Walter
Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer
Ke-Jing Tang; Jerfiz D. Constanzo; Niranjan Venkateswaran; Margherita Melegari; Mariya Ilcheva; Julio C. Morales; Ferdinandos Skoulidis; John V. Heymach; David A. Boothman; Pier Paolo Scaglioni
Author Choice
Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
Corey Speers; Shuang G. Zhao; Vishal Kothari; Alyssa Santola; Meilan Liu; Kari Wilder-Romans; Joseph Evans; Nidhi Batra; Harry Bartelink; Daniel F. Hayes; Theodore S. Lawrence; Powel H. Brown; Lori J. Pierce; Felix Y. Feng
Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate
Perparim Limani; Michael Linecker; Ekaterina Kachaylo; Christoph Tschuor; Philipp Kron; Andrea Schlegel; Udo Ungethuem; Jae Hwi Jang; Stavroula Georgiopoulou; Claude Nicolau; Jean-Marie Lehn; Rolf Graf; Bostjan Humar; Pierre-Alain Clavien
Biology of Human Tumors
Author Choice
Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor–Positive Breast Cancer
Hetal Patel; Rezvan Abduljabbar; Chun-Fui Lai; Manikandan Periyasamy; Alison Harrod; Carolina Gemma; Jennifer H. Steel; Naina Patel; Claudia Busonero; Dena Jerjees; Judit Remenyi; Sally Smith; Jennifer J. Gomm; Luca Magnani; Balázs Győrffy; Louise J. Jones; Frances Fuller-Pace; Sami Shousha; Laki Buluwela; Emad A. Rakha; Ian O. Ellis; R. Charles Coombes; Simak Ali
Author Choice
Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer
Xingjun Guo; Lei Zheng; Jianxin Jiang; Yan Zhao; Xin Wang; Ming Shen; Feng Zhu; Rui Tian; Chengjian Shi; Meng Xu; Xu Li; Feng Peng; Hang Zhang; Yechen Feng; Yu Xie; Xiaodong Xu; Wei Jia; Ruizhi He; Chencheng Xie; Jun Hu; Dawei Ye; Min Wang; Renyi Qin
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds